参考资料: https://www.amgen.com/newsroom/press-releases/2021/12/amgen-announces-positive-topline-results-from-otezla-apremilast-phase-3-discreet-study-in-moderate-to-severe-genital-psoriasis
Otezla is the leading treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S.—the treatment of patients with moderate-to-severe plaque ps...
FDA Clears Apremilast ( DENVER — At higher doses, the investigational human monoclonal antibody guselkumab outperforms adalimumab in the treatment of moderate to severe plaque psoriasis, according to a new study. "The results are very encouraging. The drug demonstrates really good safety and excellen...
2Fiorillo L, et al. Efficacy and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 52-Week Results From the SPROUT Randomized Controlled Trial. AAD Annual Meeting,March 2024. 3Brunasso AMG and Massone C. Recent advances in palmoplantar pustulosis. ...
Clinical Response in Subjects with Mild to Moderate Plaque Psoriasis The proportions of subjects who achieved an sPGA response, Whole Body Itch NRS response, and an ScPGA response at Week 16 are presented in Table 12. Table 12: Efficacy Results at Week 16 in Adults with Mild to Moderate Pla...
Moderate to severe plaque psoriasis in children who are candidates for phototherapy or systemic therapy. Oral ulcers associated with Behçet's disease. Action Action Action Acts as an inhibitor of phosphodiesterase type 4 (PDE4). Inhibition of PDE4 results in ↑ intracellular levels of cyclic aden...
(PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients with psoriasis ...
Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; an...
Amgen announced that the US District Court for the District of New Jersey has upheld patents that protect Amgen's psoriasis therapy Otezla (apremilast) in a patent infringement lawsuit against Sandoz Inc. (Sandoz) and Zydus Pharmaceuticals (USA), Inc. (Zydus). ...
Tofacitinib, an oral inhibitor of JAK3, JAK1, and, to a lesser degree, JAK2, approved for the treatment of rheumatoid arthritis in several countries, has demonstrated positive results in psoriasis in phase II studies. Studies in PsA are ongoing. With these new developments, treatment options ...